Clinical Trial

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.
Trial Details
NCT Number NCT07501156
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Enrollment 30 participants
Start Date 2026-03-18
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-30